In a cavernous office in London's AI hub, a group of researchers is preparing to do battle with humanity's oldest enemy.
Isomorphic Labs, a spinoff of Google DeepMind and the brainchild of AI pioneer Demis Hassabis , has an ambitious mission even by the standards of other AI labs: using AI to create drugs that could cure cancer and make disease a thing of the past.
Max Jaderberg, Isomorphic's president and the person running day-to-day operations at the company under Hassabis' aegis as CEO, knows it's a lofty goal. Even so, he is unfazed.
"It's a ridiculous statement, but we really say it with a straight face," said Jaderberg, 36, who spoke to Business Insider in an exclusive interview in September. He added that the rate at which Isomorphic employees were coming to him with internal breakthroughs had accelerated from monthly to weekly in the past three years.
"There's no world in five years' time, where all drugs aren't designed by AI," he said.
Right now, that goal seems a long way away.…